

MenQuadfi[®], Meningococcal (Groups A, C, Y, W) conjugate vaccine – Expanded indication

- On May 23, 2025, the <u>FDA approved</u> Sanofi's <u>MenQuadfi, Meningococcal (Groups A, C, Y, W) conjugate vaccine</u>, for active immunization for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. **MenQuadfi is approved for use in individuals 6 weeks of age and older**.
 - MenQuadfi was previously approved for this indication in individuals 2 years of age and older
 - MenQuadfi does not prevent N. meningitidis serogroup B disease.
- The approval of MenQuadfi for the expanded indication was based on immunogenicity studies comparing MenQuadfi to GSK's vaccine, <u>Menveo®</u>.
- The most common adverse reactions (≥ 10%) with MenQuadfi use in infants 6 weeks through 23 months of age are as follows:
 - 4-dose series given at 2, 4, 6, and 12 through 18 months of age: tenderness, erythema, and swelling at the injection site; irritability, crying abnormal, drowsiness, appetite lost, fever, and vomiting
 - 2-dose series given at 6 through 7 months and 12 through 13 months of age: tenderness, erythema, and swelling at the injection site; irritability, crying abnormal, drowsiness, appetite lost, fever, and vomiting.
- MenQuadfi is administered as a 0.5 mL injection intramuscularly. Refer to the drug label for the complete dosing schedule.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.